(MedPage Today) — The FDA approved pembrolizumab (Keytruda) for patients with PD-L1-positive resectable locally advanced head and neck squamous cell carcinoma as neoadjuvant monotherapy, continued as adjuvant therapy plus radiotherapy with or…
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/116058
Author :
Publish date : 2025-06-13 14:51:00
Copyright for syndicated content belongs to the linked Source.
